bioRxiv ScienceSearch

bioRxiv · 10.1101/2020.06.25.170720

In vitro activity evaluation of Lippia alba essential oil against Zika virus

Abstract

III.The Zika virus (ZIKV) of the Flaviviridae family is an emerging virus that caused, between 2016 and 2018, serious public health problems in Latin America, affecting neonates with greater severity. The clinical spectrum includes Guillain-Barre syndrome, microcephaly and others neurodegenerative diseases. There is no antiviral treatment or vaccine against this virus, for that reason the antiviral properties of various plants are being studied. Lippia alba, locally known as "Prontoalivio", is an aromatic shrub of the Verbenaceae family with a wide geographical distribution (especially in South and Central America) and is used in traditional medicine against fever, skin diseases and as a pain reliever. In this study, the antiviral activity of the essential oil of Lippia alba against ZIKV was evaluated in the Vero 76 cell line. Lippia alba was collected in the department of Amazonas, in the rainforest of Peru, and identified in the Museo de Historia Natural of the Universidad Nacional Mayor de San Marcos. The essential oil sample was obtained by steam hydrodistillation. The essential oil showed cytotoxicity to a concentration greater than or equal to 167 g/mL in the Vero 76 cell line. The antiviral activity of essential oil against ZIKV (previously identified by real-time PCR and propagated in the C6/36 cell line) was evaluated using the plaque reduction test (PRP). The essential oil showed antiviral activity in concentrations from 8.02 g/mL to 20.88 g/mL, which represents a range between 59.44% to 85.56% of plaque reduction and may be considered as a candidate for antiviral studies against ZIKV. IV. Author SummaryEnvironmental temperature fluctuations, human activities and vector characteristics increase ZIKV cases worldwide. This neglected disease has been silently affecting people of all ages, generating greater impact on neonates by causing microcephaly and other neurodegenerative diseases. ZIKV vaccines are in phase II trials and there is no antiviral treatment. Nowadays, the study of antiviral plants is gaining strength in the scientific community because they are known to contain chemical compounds that could be drugs candidates. In Peru, there are no antiviral treatments studies reported against Zika virus, this first report is important because it creates a new line of research for future studies of antiviral plant extracts against neglected viral-diseases. Finally, the essential oil of Lippia alba showed antiviral activity against ZIKV in Vero 76 cells, moreover, we intend to carefully isolate and study the chemical compounds as drug candidates in animals trials and possible humans trials. DisclaimerThe views expressed in this manuscript are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. Copyright statementJuan Sulca is an employee of the U.S. Government. This work was prepared as part of their official duties. Title 17 U.S.C. [§] 105 provides that Copyright protection under this title is not available for any work of the United States Government. Title 17 U.S.C. [§] 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that persons official duties.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Quispe-Bravo, B. E., Sevilla Drozdek, L. A., Hermosilla Jara, J., Collantes Diaz, I. E., Luiz Durigon, E., Mamani Zapana, E. W., Mayta Huatuco, E. M., Sulca Herencia, J. S.. 2020-06-25. In vitro activity evaluation of Lippia alba essential oil against Zika virus. https://doi.org/10.1101/2020.06.25.170720

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology

Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro

Background and PurposeRepurposing of currently available drugs is a valuable strategy to tackle the consequences of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on SARS-CoV-2 in cell culture models as well as in clinical practice. Our aim was to expand these studies and test some of these compounds against newly emerged variants. Experimental ApproachSeveral antidepressant drugs and antipsychotic drugs with different primary mechanisms of action were tested in ACE2/TMPRSS2-expressing human embryonic kidney cells against the infection by SARS-CoV-2 spike protein-dependent pseudoviruses. Some of these compounds were also tested in human lung epithelial cell line, Calu-1, against the first wave (B.1) lineage of SARS-CoV-2 and the variants of concern, B.1.1.7 and B.1.351. Key ResultsSeveral clinically used antidepressants, including fluoxetine, citalopram, reboxetine, imipramine, as well as antipsychotic compounds chlorpromazine, flupenthixol, and pimozide inhibited the infection by pseudotyped viruses with minimal effects on cell viability. The antiviral action of several of these drugs was verified in Calu-1 cells against the (B.1) lineage of SARS-CoV-2. By contrast, the anticonvulsant carbamazepine, and novel antidepressants ketamine and its derivatives as well as MAO and phosphodiesterase inhibitors phenelzine and rolipram, respectively, showed no activity in the pseudovirus model. Furthermore, fluoxetine remained effective against pseudo viruses with N501Y, K417N, and E484K spike mutations, and the VoC-1 (B.1.1.7) and VoC-2 (B.1.351) variants of SARS-CoV-2. Conclusion and ImplicationsOur study confirms previous data and extends information on the repurposing of these drugs to counteract SARS-CoV-2 infection including different variants of concern.

pharmacology and toxicology